CTIS2023-503647-34-00Active, not recruitingPhase 1
D.01.01.2.03
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 92
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 64 (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Phase 1
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid TumoursAdvanced or refractory solid tumoursCTIS2023-504897-39-00Deuteroncology60
Active, not recruiting
Phase 1
A phase 2 evaluation for patients who undego kidney transplant requires long term theraphy that suppress immune response to prevent damage rejection by stopping the immune system from attacking the healthy tissues in the body.EUCTR2013-002090-21-ATBristol-Myers Squibb International Corporation240
Recruiting
Phase 1
A Study of NB003 in Patients With Advanced MalignanciesCTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290
Active, not recruiting
Phase 1
Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.CTIS2023-509210-10-00niversitair Medisch Centrum Utrecht24
Active, not recruiting
Phase 1
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001Chronic Hepatitis BCTIS2023-504288-18-00Zhejiang Yaoyuan Biotechnology Co. Ltd.119